Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Results: 1 to 20 of 2064

2.
3.

Inhibition of human Arno Sec7 domain-mediated nucleotide exchange in delta17 Arf1 (17 to 181) at 2 mM by BODIPY-GTP based time resolved fluorescence assay relative to control

Source:
ChEMBL
Protein Target:
Cytohesin-2; ARF exchange factor; ARF nucleotide-binding site opener; Protein ARNO; PH, SEC7 and coiled-coil domain-containing protein 2
4.

Inhibition of human Arno Sec7 domain-mediated nucleotide exchange in delta17 Arf1 (17 to 181) assessed as residual activity at 2 mM by BODIPY-GTP based time resolved fluorescence polarization assay relative to control

Source:
ChEMBL
Protein Target:
Cytohesin-2; ARF exchange factor; ARF nucleotide-binding site opener; Protein ARNO; PH, SEC7 and coiled-coil domain-containing protein 2
5.

Inhibition of human Arno Sec7 domain-mediated nucleotide exchange in delta17 Arf1 (17 to 181) by BODIPY-GTP based time resolved fluorescence assay [Confirmatory]

Source:
ChEMBL
Protein Target:
Cytohesin-2; ARF exchange factor; ARF nucleotide-binding site opener; Protein ARNO; PH, SEC7 and coiled-coil domain-containing protein 2
6.

Inhibition of human Alexa 488 labeled Arno Sec7 domain-mediated promiscuous aggregator activity in delta17 Arf1 (17 to 181) at 1 to 100 uM by fluorescence anisotropy assay

Source:
ChEMBL
Protein Target:
Cytohesin-2; ARF exchange factor; ARF nucleotide-binding site opener; Protein ARNO; PH, SEC7 and coiled-coil domain-containing protein 2
7.

Inhibition of human Alexa 488 labeled Arno Sec7 domain-mediated promiscuous aggregator activity in delta17 Arf1 (17 to 181) at 100 uM by fluorescence anisotropy assay

Source:
ChEMBL
Protein Target:
Cytohesin-2; ARF exchange factor; ARF nucleotide-binding site opener; Protein ARNO; PH, SEC7 and coiled-coil domain-containing protein 2
8.

Inhibition of human Alexa 488 labeled Arno Sec7 domain-mediated promiscuous aggregator activity in delta17 Arf1 (17 to 181) at >20 uM by fluorescence anisotropy assay

Source:
ChEMBL
Protein Target:
Cytohesin-2; ARF exchange factor; ARF nucleotide-binding site opener; Protein ARNO; PH, SEC7 and coiled-coil domain-containing protein 2
9.

Binding affinity to human Arno Sec7 domain immobilized on CAP sensor chip at 1 mM after 15 mins by 1H 1D-NMR-700 MHz spectra analysis

Source:
ChEMBL
Protein Target:
Cytohesin-2; ARF exchange factor; ARF nucleotide-binding site opener; Protein ARNO; PH, SEC7 and coiled-coil domain-containing protein 2
10.

Binding affinity to human Arno Sec7 domain immobilized on CAP sensor chip at 250 uM by surface plasmon resonance analysis

Source:
ChEMBL
Protein Target:
Cytohesin-2; ARF exchange factor; ARF nucleotide-binding site opener; Protein ARNO; PH, SEC7 and coiled-coil domain-containing protein 2
11.

Binding affinity to human Arno Sec7 domain immobilized on CAP sensor chip after 15 mins by 1H 1D-NMR-700 MHz spectra analysis [Confirmatory]

Source:
ChEMBL
Protein Target:
Cytohesin-2; ARF exchange factor; ARF nucleotide-binding site opener; Protein ARNO; PH, SEC7 and coiled-coil domain-containing protein 2
12.

Inhibition of human Arno Sec7 domain-mediated nucleotide exchange in delta17 Arf1 (17 to 181) at 1 mM by BODIPY-GTP based time resolved fluorescence assay relative to control

Source:
ChEMBL
Protein Target:
Cytohesin-2; ARF exchange factor; ARF nucleotide-binding site opener; Protein ARNO; PH, SEC7 and coiled-coil domain-containing protein 2
13.

Inhibition of human Arno Sec7 domain binding to immobilized delta17 Arf1 (17 to 181) at 1 mM after 15 mins by BODIPY-GTP based time resolved fluorescence assay relative to control

Source:
ChEMBL
Protein Target:
Cytohesin-2; ARF exchange factor; ARF nucleotide-binding site opener; Protein ARNO; PH, SEC7 and coiled-coil domain-containing protein 2
14.

Inhibition of AKT2 (unknown origin)using GSK3 (14 to 27) as substrate after 60 mins by scintillation counting

Source:
ChEMBL
Protein Target:
RAC-beta serine/threonine-protein kinase; Protein kinase Akt-2; Protein kinase B beta; PKB beta; RAC-PK-beta
15.

Inhibition of human PKBbeta assessed as residual activity at 1 uM relative to control

Source:
ChEMBL
Protein Target:
RAC-beta serine/threonine-protein kinase; Protein kinase Akt-2; Protein kinase B beta; PKB beta; RAC-PK-beta
16.

Inhibition of human PKBbeta assessed as residual activity at 1 uM relative to control

Source:
ChEMBL
Protein Target:
RAC-beta serine/threonine-protein kinase; Protein kinase Akt-2; Protein kinase B beta; PKB beta; RAC-PK-beta
17.

Inhibition of AKT2 (unknown origin) at 30 uM

Source:
ChEMBL
Protein Target:
RAC-beta serine/threonine-protein kinase; Protein kinase Akt-2; Protein kinase B beta; PKB beta; RAC-PK-beta
18.

Inhibition of human wild type AKT2 at 1 uM by qPCR analysis

Source:
ChEMBL
Protein Target:
RAC-beta serine/threonine-protein kinase; Protein kinase Akt-2; Protein kinase B beta; PKB beta; RAC-PK-beta
19.

Inhibition of human PKBbeta assessed as residual activity at 10 uM relative to control

Source:
ChEMBL
Protein Target:
RAC-beta serine/threonine-protein kinase; Protein kinase Akt-2; Protein kinase B beta; PKB beta; RAC-PK-beta
20.

Inhibition of human PKBbeta assessed as residual activity at 1 uM relative to control

Source:
ChEMBL
Protein Target:
RAC-beta serine/threonine-protein kinase; Protein kinase Akt-2; Protein kinase B beta; PKB beta; RAC-PK-beta

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Refine your results

• What's this?

Actions on your results

Find related data

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk